{"disease":{"id":"cyclophosphamide","name":"cyclophosphamide"},"drugs":{"marketed":[{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Light Chain (AL) Amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05495893","title":"MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":224,"lead_sponsor_name":"Second Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT05886335","title":"Influence of Timing PTCy in AlloSCT","phase":"","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT05158608","title":"Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"National Research Center for Hematology, Russia","has_results":false},{"nct_id":"NCT06695741","title":"Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03373019","title":"Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04464434","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT00590785","title":"Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03200002","title":"Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Chitwan Medical College","has_results":false},{"nct_id":"NCT05150080","title":"Early Identification and Evaluation of Cyclophosphamide Cardiotoxicity","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Kai Mu","has_results":false},{"nct_id":"NCT05850845","title":"Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT04489420","title":"Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Celularity Incorporated","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}